gp130 Inhibitors

gp130 inhibitors encompass a diverse range of chemical compounds that directly or indirectly modulate the activity of gp130, a crucial component of the IL-6 receptor complex involved in various cellular processes. Among the inhibitors listed, several directly target downstream effectors of gp130, particularly the Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway. SC144, Stattic, S3I-201, and SH-4-54 are small molecules known to specifically inhibit the gp130/STAT3 signaling axis. These compounds act by disrupting STAT3 activation downstream of gp130, providing researchers with precise tools to investigate the role of this pathway in diverse physiological and pathological contexts. Cryptotanshinone and HO-3867, both natural and synthetic inhibitors, respectively, also target STAT3, shedding light on the value of natural products in modulating gp130-associated pathways. Napabucasin and BP-1-102, among others, further contribute to the repertoire of gp130 inhibitors by offering insights into the intricate regulatory mechanisms governing gp130-mediated cellular responses. Napabucasin, in particular, targets the gp130/STAT3 signaling pathway. Tocilizumab, a monoclonal antibody targeting the IL-6 receptor, indirectly inhibits gp130-mediated signaling by preventing IL-6 binding.